Abstract
Methods: In this study, we used the multiplex bead-based Eve Technologies Discovery assay and the aptamerbased SomaLogic SOMAscan assay to identify circulating proteins predictive of response to immunotherapy in melanoma patients treated with combination immune checkpoint inhibitors. Expression of four plasma proteins were further validated using the bead-based Millipore Milliplex assay.
Results: Both the Discovery and the SOMAscan assays detected circulating plasma proteins in immunotherapy-treated melanoma patients. However, these widely used assays showed limited correlation in relative protein quantification, due to differences in specificity and the dynamic range of protein detection. Protein data derived from the Discovery and Milliplex bead-based assays were highly correlated.
Conclusions: Our study highlights significant limitations imposed by inconsistent sensitivity and specificity due to differences in the detection antibodies or aptamers of these widespread biomarker discovery approaches. Our findings emphasize the need to improve these technologies for the accurate identification of biomarkers.
| Language | English |
|---|---|
| Article number | 32 |
| Pages | 1-12 |
| Number of pages | 12 |
| Journal | Biomarker research |
| Volume | 5 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Bibliographical note
Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- Cytokines
- Multiplexing
- Luminex
- Aptamers
- SOMAscan
- Biomarkers
- Liquid biopsies
- Immune checkpoint inhibitors
- Melanoma
Cite this
}
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. / Lim, Su Yin; Lee, Jenny; Welsh, Sarah J.; Ahn, Seong Beom; Breen, Edmond; Khan, Alamgir; Carlino, Matteo S.; Menzies, Alexander M.; Kefford, Richard F.; Scolyer, Richard A.; Long, Georgina V.; Rizos, Helen.
In: Biomarker research, Vol. 5, 32, 2017, p. 1-12.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.
AU - Lim, Su Yin
AU - Lee, Jenny
AU - Welsh, Sarah J.
AU - Ahn, Seong Beom
AU - Breen, Edmond
AU - Khan, Alamgir
AU - Carlino, Matteo S.
AU - Menzies, Alexander M.
AU - Kefford, Richard F.
AU - Scolyer, Richard A.
AU - Long, Georgina V.
AU - Rizos, Helen
N1 - Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2017
Y1 - 2017
N2 - Background: Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the identification of biomarkers is critical for the selection and management of patients receiving treatment. Biomarker discovery often involves proteomic techniques that simultaneously profile multiple proteins but few studies have compared these platforms.Methods: In this study, we used the multiplex bead-based Eve Technologies Discovery assay and the aptamerbased SomaLogic SOMAscan assay to identify circulating proteins predictive of response to immunotherapy in melanoma patients treated with combination immune checkpoint inhibitors. Expression of four plasma proteins were further validated using the bead-based Millipore Milliplex assay.Results: Both the Discovery and the SOMAscan assays detected circulating plasma proteins in immunotherapy-treated melanoma patients. However, these widely used assays showed limited correlation in relative protein quantification, due to differences in specificity and the dynamic range of protein detection. Protein data derived from the Discovery and Milliplex bead-based assays were highly correlated. Conclusions: Our study highlights significant limitations imposed by inconsistent sensitivity and specificity due to differences in the detection antibodies or aptamers of these widespread biomarker discovery approaches. Our findings emphasize the need to improve these technologies for the accurate identification of biomarkers.
AB - Background: Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the identification of biomarkers is critical for the selection and management of patients receiving treatment. Biomarker discovery often involves proteomic techniques that simultaneously profile multiple proteins but few studies have compared these platforms.Methods: In this study, we used the multiplex bead-based Eve Technologies Discovery assay and the aptamerbased SomaLogic SOMAscan assay to identify circulating proteins predictive of response to immunotherapy in melanoma patients treated with combination immune checkpoint inhibitors. Expression of four plasma proteins were further validated using the bead-based Millipore Milliplex assay.Results: Both the Discovery and the SOMAscan assays detected circulating plasma proteins in immunotherapy-treated melanoma patients. However, these widely used assays showed limited correlation in relative protein quantification, due to differences in specificity and the dynamic range of protein detection. Protein data derived from the Discovery and Milliplex bead-based assays were highly correlated. Conclusions: Our study highlights significant limitations imposed by inconsistent sensitivity and specificity due to differences in the detection antibodies or aptamers of these widespread biomarker discovery approaches. Our findings emphasize the need to improve these technologies for the accurate identification of biomarkers.
KW - Cytokines
KW - Multiplexing
KW - Luminex
KW - Aptamers
KW - SOMAscan
KW - Biomarkers
KW - Liquid biopsies
KW - Immune checkpoint inhibitors
KW - Melanoma
U2 - 10.1186/s40364-017-0112-9
DO - 10.1186/s40364-017-0112-9
M3 - Article
VL - 5
SP - 1
EP - 12
JO - Biomarker research
T2 - Biomarker research
JF - Biomarker research
SN - 2050-7771
M1 - 32
ER -